← Every applicant
Biocon Pharma FDA Approvals
27 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| NINTEDANIB ESYLATENew drugAug 19, 2026CAPSULE, ORAL |
| TOPIRAMATENew drugJul 22, 2026CAPSULE, EXTENDED RELEASE, ORAL |
| DEFLAZACORTNew drugMay 28, 2026SUSPENSION, ORAL |
| ELTROMBOPAG OLAMINENew drugApr 28, 2026TABLET, ORAL |
| DAPAGLIFLOZINNew drugApr 6, 2026TABLET, ORAL |
| LIRAGLUTIDENew drugMar 11, 2026SOLUTION, SUBCUTANEOUS |
| LIRAGLUTIDENew drugFeb 24, 2026SOLUTION, SUBCUTANEOUS |
| EVEROLIMUSNew drugJan 9, 2026TABLET, FOR SUSPENSION, ORAL |
| TOFACITINIB CITRATENew drugNov 17, 2025TABLET, EXTENDED RELEASE, ORAL |
| RIVAROXABANNew drugMay 14, 2025TABLET, ORAL |
| EVEROLIMUSNew drugApr 9, 2025TABLET, ORAL |
| NOREPINEPHRINE BITARTRATENew drugMar 21, 2025INJECTABLE, INJECTION |
| DASATINIBNew drugMar 3, 2025TABLET, ORAL |
| LENALIDOMIDENew drugMar 3, 2025CAPSULE, ORAL |
| NITROFURANTOINNew drugOct 28, 2024SUSPENSION, ORAL |
| SACUBITRIL AND VALSARTANNew drugAug 30, 2024TABLET, ORAL |
| DAPTOMYCINNew drugAug 29, 2024POWDER, INTRAVENOUS |
| MICAFUNGIN SODIUMNew drugMay 29, 2024INJECTABLE, INTRAVENOUS |
| OXCARBAZEPINENew drugMar 1, 2024SUSPENSION, ORAL |
| LIOTHYRONINE SODIUMNew drugFeb 6, 2024TABLET, ORAL |
| MYCOPHENOLATE SODIUMNew drugNov 29, 2023TABLET, DELAYED RELEASE, ORAL |
| TERIFLUNOMIDENew drugMar 13, 2023TABLET, ORAL |
| ATORVASTATIN CALCIUMNew drugNov 23, 2022TABLET, ORAL |
| PEMETREXED DISODIUMNew drugMay 25, 2022POWDER, INTRAVENOUS |
| POSACONAZOLENew drugFeb 4, 2022TABLET, DELAYED RELEASE, ORAL |
| MYCOPHENOLATE SODIUMNew drugNov 29, 2021TABLET, DELAYED RELEASE, ORAL |
| EVEROLIMUSNew drugFeb 11, 2021TABLET, ORAL |